Department of Neurosciences and Mental Health, Fondazione IRCCS Ca'Granda Ospedale Maggiore Policlinico, Milan, Italy.
Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.
Int J Psychiatry Clin Pract. 2021 Mar;25(1):82-89. doi: 10.1080/13651501.2020.1865405. Epub 2020 Dec 30.
Objective of the present manuscript is to investigate, among Italian early career psychiatrists (ECPs), prescriber and patient-related factors associated with lithium or valproate preference to treat patients affected by Bipolar Disorder (BD).
An on-line survey was carried out among 252 ECPs, investigating their prescription patterns in relation to lithium and the differences with prescription of valproate. Collected data were compared according to lithium or valproate prescription preference in the long-term treatment of BD by tests for qualitative variables.
Over two thirds of ECPs preferred lithium over valproate for the maintenance treatment of BD. Less than half of the sample used lithium as first-line agent for mania or major depression, and less than one third for mixed episodes. Factors associated with lithium preference as first-line maintenance treatment include perception of having a good knowledge of lithium ( < 0.001) and complete satisfaction with education on lithium ( < 0.001). One of the main factors to prefer valproate was the concern about long-term side effects of lithium ( < 0.001).
Type of education, source of information, clinical experience and safety concerns influence the choice of lithium versus valproate in the long-term treatment of BD. Present findings may guide educational training of ECPs.KEY POINTSLithium has been less prescribed in the last years for long-term treatment of Bipolar Disorder.Educational and clinical factors seem to influence the attitude to prescribe lithium.Only half of the Italian early career psychiatrists declare to have at least an adequate knowledge of lithium.Residency program in psychiatry should consider the implementation of education on lithium.
本研究旨在调查意大利年轻精神科医生(ECPs)中与锂或丙戊酸盐治疗双相情感障碍(BD)患者偏好相关的处方者和患者相关因素。
对 252 名 ECP 进行了在线调查,调查他们与锂相关的处方模式以及与丙戊酸盐处方的差异。根据锂或丙戊酸盐在 BD 长期治疗中的处方偏好,采用 检验比较收集的数据。
超过三分之二的 ECP 更倾向于使用锂来维持 BD 的治疗。不到一半的样本将锂作为治疗躁狂或重度抑郁的一线药物,不到三分之一的样本用于治疗混合发作。作为一线维持治疗首选锂的因素包括对锂有较好了解的认知( < 0.001)和对锂教育的完全满意( < 0.001)。选择丙戊酸盐的主要因素之一是担心锂的长期副作用( < 0.001)。
教育类型、信息来源、临床经验和安全性考虑会影响在 BD 的长期治疗中选择锂或丙戊酸盐。目前的研究结果可能为 ECPs 的教育培训提供指导。
锂在过去几年中较少用于 BD 的长期治疗。教育和临床因素似乎会影响锂的处方态度。只有一半的意大利年轻精神科医生声称对锂有至少足够的了解。精神科住院医师培训项目应考虑开展锂教育。